GlobalData on MSN1d
MindMed doses first subject in trial of tablets for generalised anxiety disorder
US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...
Breakthrough Study: Natural Compound Could Counter Opioid Addiction Without Sacrificing Pain Relief
Boosting the endocannabinoid 2-AG in the brain can counteract opioid addiction while preserving their pain relief, a Weill ...
Business Wire2d
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...
Medscape6d
Few Focal Epilepsy Cases Controlled by Initial ASM Treatment
Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications, new ...